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Macrolide antibiotics (MAs) have a wide spectrum of activities
against Gram-positive bacteria, but they have also been proposed as
anticancer drugs for multiple tumor types.1 On these bases, clinical
trials have been started, and their results evidenced clinical
beneﬁts.1 MAs have also been tested in hematologic malignancies,
alone or in combination with chemotherapeutic drugs or tyrosine
kinase inhibitors.2,3 How MAs exert antineoplastic activity is unclear.
Different mechanisms have been proposed, including modulation of
autophagy.4–6
We tested the activity of two MAs, clarithromycin (Cla) and
erythromycin (Er), on acute leukemia (AL) cells, both myeloid
and lymphoid. Both MAs induced leukemia cell death in our cell
lines. Cla was efﬁcacious in AML cells, whereas the LD50 (dose
lethal to 50% of animals tested) values of Er, although higher
compared with Cla, were generally lower in ALL cells (representa-
tive IC50 (half-maximal inhibitory concentration) values of both
MAs are shown in Figure 1a, whereas all the data are reported in
Supplementary Table S1).
Next, we tested whether MAs affected the autophagic process of
AL cell. Cla-induced vacuoli formation (Supplementary Figure S1)
and the conversion of the light chain enhancer 3 (LC3) from its
soluble (LC3I) to the membrane-bound form LC3II, in FLG 29.1 AML
cells (Figure 1b left panel and Supplementary Figure S2). Both the
effects indicate triggering of autophagy. Similar results were
obtained after treatment of 697 ALL cells with Er (Figure 1b right
panel and Supplementary Figure S2). The autophagic ﬂux was
determined by ﬂow-cytometry, measuring cyto-ID-stained autopha-
gic compartments through the Cyto-ID Green Detection Reagent
(Supplementary Information). Cla induced an increase in Cyto-ID
ﬂuorescence in FLG 29.1 cells (Figure 1c, upper panel). This indicates
an impairment in autophagic ﬂux. Similar effects were produced by
Er on 697 cells (Figure 1c, lower panel).
Autophagy is regulated by different signaling pathways: the PI3K/
Akt pathway, which inhibits autophagy by interacting with mTORC1,
and the Erk1/2 pathway, which activates autophagy and promotes
cell survival.4,7 Cla determined an early decrease in both Akt and
Erk1/2 phosphorylation (Figure 1d and Supplementary Figure S2).
The former effect is consistent with autophagy activation, whereas
the latter points to inhibition of prosurvival signals and hence
induction of apoptosis. Consistently, Cla induced the activation
of caspase 3 in FLG 29.1 cells (Figure 1e and Supplementary
Figure S2). Overall, MAs stimulate autophagy in AL cells through
the inhibition of Akt, but they subsequently block the autophagic
ﬂux and induce autophagic cell death. In parallel, MAs also inhibit
the Erk-dependent survival signals, thus triggering apoptosis. In
other words, MAs activate both autophagic and apoptotic cell
death in AL cells.
MAs can block hERG1 currents in reconstitued cellular models.8,9
Conversely, blocking hERG1 has antileukemic effects both in vitro
and in vivo.10–12 Therefore, we hypothesized that the effects of MAs
on AL cells could depend on hERG1 inhibition. We ﬁrst evaluated
the effects of MAs on hERG1 currents of AL cells, using Cla
and the AML cell line FLG 29.1 as a model (details are given
in Supplementary Figure S3). Cla inhibited hERG1 currents in
a concentration-dependent manner (IC50 = 38.5 ± 7.0 μM). It also
reduced hERG1B currents (IC50 = 66.8 ± 9.8 μM), that is, the main
hERG1 isoform expressed in leukemia cells.13,14 Therefore, Cla
blocks hERG1B with high efﬁcacy, differently from classical
hERG1 blockers like E4031.
Next, we studied the effects of hERG1 blocking (treatment with
E4031) and silencing on the autophagic process. For the latter
purposes, the level of autophagy in hERG1-silenced FLG 29.1 cells
(FLG 29.1-sh7, whose characterization is shown in Supplementary
Figure S4) was compared with that of cells infected with the
empty vector (FLG 29.1 pLKO). hERG1 blockade induced a time-
dependent increase in the percentage of cells with vacuoles
(Supplementary Figure S1), paralleled by increased levels of LC3II
(Figure 1f left panel and Supplementary Figure S2). Similar effects
were obtained with the hERG1B-selective blocker, CD160130(ref. 12)
(Figure 1f right panel and Supplementary Figure S2). Moreover
FLG 29.1 cells treated with E4031 showed an increase of AAF
(Figure 1g). Hence, blocking hERG1 triggers autophagy and blocks
the autophagic ﬂux, similarly to MAs. Consistently, FLG 29.1-sh7
cells showed an increased percentage of cells with vacuoli
(Supplementary Figure S1), increased levels of LC3II (Figure 1h
and Supplementary Figure S2), but unchanged levels of MFI
relative to the cyto-ID-stained autophagic compartments, com-
pared with FLG pLKO cells (mean 258 ± 7 vs 266 ± 11; Figure 1i).
Hence, silencing hERG1 triggers autophagy but, at difference with
hERG1 blockade, does not impair the autophagy ﬂux. Consistently,
blocking hERG1 with E4031 or silencing its expression both
induced a decrease in Akt and Erk 1/2 phosphorylation (Figure 1j
and Supplementary Figure S2), but only E4031 led to activation of
caspase 3, which triggers apoptotic cell death (Figure 1k and
Supplementary Figure S2). Overall, these data conﬁrm the
hypothesis that hERG1 modulates the autophagic ﬂux in AL cells,
and that pharmacologically blocking the channel triggers
autophagy, but blocks the autophagic ﬂux, thus inducing both
autophagic and apoptotic cell death, in analogy to MAs.
Finally, we tested whether the effects of MAs on AL cell death
was related to their blocking effect on hERG1 currents. MAs were
tested on hematopoietic cells that do not express the hERG1
channel: normal peripheral blood mononuclear cells (PBMNCs),
and EBV infected B lymphocytes (EBV-B).11 Cla poorly affected
both PBMNCs and EBV-B cells, showing LD50 values higher than
200 μM (Supplementary Figure S5). Cla had signiﬁcantly (Po0.01)
higher LD50 values in FLG 29.1-sh7 than in FLG 29.1-plkO
(Supplementary Figure S5). This is clear from Figure 1l, showing
the data obtained with 52 μM Cla in silenced and control cells.
Finally, we tested the combination of MAs and E4031 on AL cell
death. If added in conjunction with E4031, then both Cla and Er
showed a larger effect on cell death (Figure 1m). This is consistent
with the fact that MAs block hERG1 currents by binding a site
different from the one targeted by E4031.8 Overall, we conclude
that the antileukemic effect of MAs is totally or partially mediated
by their blockade of hERG1 currents.
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Figure 1. Effects of MAs Clarithromycin (Cla), Erythromycin (Er) and hERG1 blockade and silencing on autophagy in acute leukemia cells.
(a) LD50 values of Cla and Er in a panel of myeloid and lymphoid (AML cells: FLG 29.1, HL60; B cell precursor (BCP)-ALL cells: 697, REH) cell lines.
Cells were treated with different concentrations of Cla and Er for 48 h and analyzed through the Annexin V/PI test. LD50 values were evaluated
by nonlinear regression analysis using Origin 6 software (Microcal Software). Values are mean± s.e.m. of three indipendent experiments each
performed in triplicate. (b) Left panel. Western blot of light chain enhancer 3 (LC3) expression (18 and 16 kDa bands) in FLG 29.1 cells treated
with 56 μM Cla (the LD50 value as shown in a and in Supplementary Table 1S) or for different time points. LC3 was determined, as a biomarker
of the autophagic process. Reprobing of the membrane was with an anti-tubulin antibody. Densitometric analysis is reported in
Supplementary Figure S2. Right panel. Western blot of LC3 expression (18 and 16 kDa bands) in 697 cells treated with 78 μM Er (the LD50 value
as shown in Figure 2) for 2 h. Membrane reprobing as above. Densitometric analysis is reported in Supplementary Figure S2. (c) Cyto-ID ﬂow-
cytometry analysis (representative panels) of FLG 29.1 and 697 cells treated with Cla (upper panel) and Er (lower panel) at their LD50 value for
2 h. The method is detailed in Materials and Methods. The mean autophagy activity factor (AAF) value, calculated in three separate
experiments from AAF= 100 × [(MFI-treated cells−MFI-untreated cells)/MFI-treated cells] is shown on the top of each panel. (d) Western blot
of pERK1/2 (top) and pAkt (bottom) in FLG 29.1 cells treated for 30 min with 56 μM Cla. Membrane reprobing (with anti-ERK1/2 and total Akt
antibodies) as in b. Densitometric analysis is reported in Supplementary Figure S2. (e) Western blot of caspase 3 in FLG 29.1 treated for 30 min
with 56 μM Cla. Membrane reprobing as in b. Densitometric analysis is reported in Supplementary Figure S2. (f) Left panel. Western blot of LC3
expression in FLG 29.1 cells treated with 22 μM E4031 for different time points: hERG1 blockade by E4031 induced increased levels of LC3II at
least 2 h after treatment and last at least up to 24 h. Membrane reprobing was performed as in b. Densitometric analysis is reported in
Supplementary Figure S2. Right panel. Western blot of LC3 expression in FLG 29.1 cells treated with CD160130, at the LD50 value (3.5 μM) for
2 h. Membrane reprobing and was performed as in b. (g) Cyto-ID ﬂow-cytometry analysis (representative panels) of FLG 29.1 in control
conditions and after 2 h treatment with 22 μM E4031. The AAF value, calculated as in c is reported on the top. Data shown are representative of
two independent experiments. (h) Western blot of LC3 expression in FLG 29.1-sh7 and FLG 29.1-plKo. Membrane reprobing was performed as
in b. Densitometric analysis is reported in Supplementary Figure S2. (i) Cyto-ID ﬂow-cytometry analysis of FLG 29.1-sh7 and FLG 29.1-plKo
cells. A representative panel is shown. MFI values from two independent experiments are reported in the text. (j) Western blots of pERK1/2
(top) and pAkt (bottom) of FLG 29.1-sh7, FLG 29.1-plKo and FLG 29.1 cells treated or not with 22 μM E4031 for 30 min. Membrane reprobing
was performed as in b. Densitometric analysis is reported in Supplementary Figure S2. (k) Western blot of caspase 3 of FLG 29.1-sh7, FLG 29.1-
plKo and FLG 29.1 cells treated or not with 22 μM E4031 for 30 min. Membrane reprobing was performed as in b. Densitometric analysis is
reported in Supplementary Figure S2. (l) Percentage of Annexin V+/PI− cells in FLG 29.1-plkO and FLG 29.1-sh7 cells treated with 52 μM Cla for
48 h (Po0.01, Student’s t-test). (m) Percentage of Annexin V+/PI− cells in FLG 29.1-plkO cells treated with 52 μM Cla, or 78 μM Er, alone or in
combination with 22 μM E4031. Values are mean± s.e.m. of two indipendent experiments each performed in triplicate.
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We next tested the effects of MAs (both Cla and Er) in
combination with chemotherapeutic drugs commonly used to
treat either ALL (Doxorubicin, Doxo) or AML (Cytarabine, Cyt). AL
cells were cultured either in suspension or onto MSC cells, which
are known to protect leukemia cells from chemotherapy-induced
cell death (Pillozzi et al.11 references therein). Figures 2a and b
show that the addition of LD50 concentrations of either MA in
combination with chemotherapeutic drugs increased the percen-
tage of Annexin V+/propidium iodide (PI)− cells. The effect was
particularly evident in MSC-supported cultures. These results are
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corroborated by the CI values (Supplementary Table S2): MAs are
synergic with chemotherapeutic drugs, especially when added to
MSC-supported cultures. The combination of Er with prednisone (Pdn,
5 μM11 in 697 ALL cells signiﬁcantly increased the percentage of
Annexin V+/PI− cells, especially in MSC-supported cultures
(Figure 2c). Finally, Cla in combination with Cyt (at 45 nM), also
produced a signiﬁcant increase in the percentage of Annexin V+/PI−
cells in three primary AML samples co-coltured with MSC (Figure 2d).
The antileukemic effect of MAs, alone or in combination with
chemotherapeutic drugs, was then evaluated in vivo, in both AML
(HL60-luc2) and ALL (REH) mouse models. Details of both models are
given in Supplementary Information. Cla decreased the AML burden
compared to both untreated and Cyt-treated mice (Figure 1e, see also
the median values of c.p.m. for each treatment group at different
time points, in the right panel). Er reduced both bone marrow (BM)
engraftment and PB invasion of ALL cells (Figure 1f), similarly to what
was obtained with E4031 (Supplementary Figure S6).
Either MAs were then tested in combination with chemother-
apeutic drugs: mice injected with HL60 AML cells were treated with
Cla and Cyt, whereas mice injected with REH ALL cells (notoriously
resistant to corticosteroids11) were treated with Er and the
corticosteroid dexamethasone (Dexa). Combination treatment of Cla
with Cyt signiﬁcantly increased the overall survival of HL60-luc2
injected mice compared with control group (P=0.0024; Figure 1g).
Combination treatment of Er with Dexa improved overall survival,
(Figure 1h), reduced BM engraftment and roughly abolished PB
leukemia burden compared with Dexa treatment (inset to Figure 1h).
In this paper, we provide evidence that (1) MAs have
antileukemic activity, either in vitro or in vivo, in both AML and
ALL, alone or in combination with chemotherapeutic drugs, (2)
these effects depend on a complex modulation of both autophagy
and intracellular signaling pathways regulating cell survival and
apoptosis, and (3) are mediated by hERG1 channels. Compared
with hERG1 blockers, MAs have a low risk of inducing torsade-de-
points cardiac arrhythmias.9 We thus propose to include these
compounds in treatment schedules of resistant acute leukemias in
combination with chemotherapeutic drugs.15
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